Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis.
Zoë Y G J van LieropLuuk WieskeMarleen Ja Koel-SimmelinkMadhurima ChatterjeeIris DekkerCyra E LeursEline Aj WillemseBastiaan MoraalFrederik BarkhofFilip EftimovBernhard Mj UitdehaagJoep KillesteinCharlotte E TeunissenPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2021)
Lower baseline sCNTN1 concentrations were associated with long-term disability progression during natalizumab treatment, making it a possible blood-based prognostic biomarker for RRMS.